Abiomed, Inc.

Headquarters: Danvers, MA, United States

Founded: 1981

Employees: 1,725

CEO: Mr. Michael R. Minogue


Market Cap

$17.18 Billion

USD as of Dec. 1, 2022

Market Cap History

Abiomed, Inc. market capitalization over time

Evolution of Abiomed, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Abiomed, Inc.

Detailed Description

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the Automated Impella Controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; and Impella BTR, a percutaneous micro heart pump with integrated motors and sensors. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

Top 1-year algo backtest: +269.94%

$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Product & Services

Cardiovascular medical implant devices

Key People

Michael R. Minogue, CEO Thorston Siess, CTO Chuck Simonton, CMO Dr. David M. Weber, COO Andrew Greenfield, CCO


Revenue: US$840.88 million (2020)

Operating income: US$249.22 million (2020)

Net income: US$203.01 million (2020)

Total assets: US$1.2 billion (2020)

Total equity: US$1.06 billion (2020)



22 Cherry Hill Drive

Danvers, MA 01923

United States

Phone: 978 646 1400

Fax: 978 777 8411